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objective was to study this relationship and determine whether it provides evidence
of lipid lowering therapy (LLT) effectiveness in European primary care. METHODS:
The study populations were identiﬁ ed from CSD Patient Data (France, Germany, Italy)
and THIN (UK) primary care databases. Included patients received lipid lowering 
prescription drugs in the ﬁ rst 6 months of 2005 (index) and had a prescription at least 
6 months before index. Cholesterol records within 12 months after index were 
obtained. Analyses were restricted to practitioners with cholesterol reporting rate
q50%. Multivariable linear regression was applied to evaluate the association between
cholesterol level and age controlling for gender, diabetes, cardiovascular disease,
hypertension, and LLT drug. RESULTS: In France, the median cholesterol was
5.23 mmol/L for age a65 (n  15537, 63% male) compared to 5.18 for age 65 (n 
16416, 46% male). In Germany, the median cholesterol was 5.26 mmol/L for age a65 
(n  4147, 63% male) compared to 5.10 for age 65 (n  6300, 48% male). In Italy,
the median cholesterol was 5.31 mmol/L for age a65 (n  2230, 59% male) compared
to 5.15 for age 65 (n  3232, 42% male). In the UK, the median cholesterol was 
4.50 mmol/L for age a65 (n  49,208, 61% male) compared to 4.30 for age 65 (n
 67,670, 50% male). For each country, cholesterol levels decreased with increasing
age (p  0.0001) controlling for covariates. CONCLUSIONS: This study presents 
population level evidence of LLT effectiveness in primary care as cholesterol levels did 
not increase with age, as would be expected in an untreated population. Furthermore, 
levels were lower among patients with conditions that warrant aggressive therapy
indicating LLT impact.
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OBJECTIVES: Examines the clinical and economic outcomes of this therapy modiﬁ ca-
tion in a community-based physician practice. Health care practitioners are commonly 
requested by insurers and patients to switch from their current statin to simvastatin
for cost reasons. METHODS: Medical record review via an electronic medical record
from a community-based primary care ofﬁ ce was performed on patients switched by
the physician from another statin to simvastatin between January 1, 2002 to October 
31, 2008. Patients were included if they had available lipid data pre- and post-switch.
National Cholesterol Education Program (NCEP) risk categories were calculated and
associated LDL cholesterol (LDL-C) goals assigned. Primary outcomes were changes
in lipid fractions and LDL-C goal attainment, analyzed by paired t-tests and McNe-
mar’s test, respectively. Economic outcomes were modeled using current retail medica-
tion prices and Medicare costs for medical services. RESULTS: A total of 48 patients
were identiﬁ ed; atorvastatin was the most common pre-switch statin (31 patients).
The cohort had a mean age of 64.612.6 years, was 60% female and 65% were
primary prevention. Over 95% of patients were switched to an appropriate equipotent 
dose of simvastatin. Mean pre-and post-switch LDL-C levels were 104 mg/dL and 
103 mg/dL, a non-signiﬁ cant reduction of 1.225.7 mg/dL (p  0.754). Results for the 
other lipid fractions and in a subanalysis of atorvastatin switched-patients showed
similar non-signiﬁ cant changes. A non-signiﬁ cant 4.1% increase in NCEP goal attain-
ment between the pre-switch (68.8%) and post-switch (72.9%) time periods was 
observed (p  0.754). Modeled cost savings were estimated at $575/patient/year.
CONCLUSIONS: Previously treated statin patients switched to equipotent doses of 
simvastatin achieved similar LDL-C lowering and NCEP goal attainment within this 
community-based, primary care setting. These results show the potential for signiﬁ cant 
cost savings for the health care system when appropriate patients are switched using
equipotent doses. Overall, these data support the approach that appropriate switching 
decisions should be made on a case-by-case basis.
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EFFECT OF STATIN THERAPY ON RISK OF CORONARY DISEASE IN
PRIMARY AND SECONDARY PREVENTION TRIALS: A META-ANALYSIS OF 
RANDOMIZED CONTROLLED TRIALS
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OBJECTIVES: Cholesterol-lowering treatment is known to reduce risk of coronary
heart disease independent of age and gender. However, the potential treatment effect 
difference of statin therapy between primary and secondary prevention trials has 
not been clearly demonstrated. This study aimed to estimate risk reduction of 
major coronary events, coronary mortality and total mortality associated with
statin drug treatment in primary and secondary prevention trials. METHODS:
Clinical trials conducted in human subjects and published in English-language journals
were collected by retrieving MEDLINE (1966–2008), bibliographies, and authors’ 
reference ﬁ les. Studies in which participants were randomized to statin or placebo for 
at least 4 years and coronary clinical disease or death was the primary outcome were 
included in the meta-analysis. RESULTS: Data from 4 primary and 4 secondary pre-
vention trials, with 46357 participants and 5.1 years treatment duration, were
included in this study. All patients in secondary preventions trials had a history of 
either myocardial infarction or angina. Meta-analysis revealed that statin drug treat-
ment reduced absolute risk for major coronary events per 1000 by 19 (P  0.001,
95% conﬁ dence interval [CI]: 9–29), 48 (P  0.001, 95% CI: 28–67) in primary and 
secondary prevention trials, respectively; by 3 (P  0.005, 95% CI: 1–5), 20 (P  0.001,
95% CI: 17–24) for coronary mortality; by 5 (P  0.043, 95% CI: 0–11), 25 (P 
0.001, 95% CI: 15–35) for all-cause mortality. Difference in coronary mortality and 
all-cause mortality between primary and secondary prevention trials was statistically 
signiﬁ cant since the CIs had nothing overlapped. CONCLUSIONS: This study indi-
cated that statin therapy provided a decrease in the risk of major coronary events, 
coronary mortality and all-cause mortality in both primary and second prevention 
trials; but the secondary prevention trials obtained considerably more events avoided 
due to treatment.
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RISK OF RE-BLOCKING AN ARTERY AFTER A TREATMENT AS A
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OBJECTIVES: Episode Grouping is a methodology that enables health care profes-
sionals to analyze patient treatments and evaluate the quality of the treatments and 
manage the related costs. There are three procedures or treatments for a patient with 
coronary artery disease. Re-blocking an artery after a procedure directly affects the 
cost and severity of the treatment. We use statistic and probability method to examine
the information about patients with coronary artery disease and estimate the risk of 
re-blocking an artery after each procedure. METHODS: A dataset provided by an 
insurance company is used. It contained about 6,500,000 patient claims related to
year 2000–2005. Data processing is done by using SAS software and SAS codes. Then 
based on some assumptions and conditional probability the risk of re-blocking an
artery after each procedure (bare-stent, drug-eluting stent, and open bypass surgery) 
are estimated. RESULTS: Comparing the three types of procedures; bypass surgery,
drug-eluting stent, and bare stent, shows that the risk of re-blocking an artery after a 
bare stent is almost 24%, and by using the drug-eluting stent, this risk decreases to
almost 13%. Bypass surgery procedure has the lowest re-blocking rate that is less than 
7%. CONCLUSIONS: The Drug-eluting stent reduces the rate of re-blocking an artery 
to 46% compared to the bare stent. This is the main reason for shifting from the bare
stent to the drug-eluting stent and makes the drug-eluting stent more effective. But the 
rate of re-blocking after the drug-eluting stent is still about 6% more than the rate of 
re-blocking after an open bypass surgery. The main question remaining is how we 
can estimate the severity and quality of life after each procedure and justify the cost-
effectiveness of one of this procedure.
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OBJECTIVES: To determine the association between pharmacy treatments (ACE
Inhibitors (ACEI), Beta-blockers (BB)) and outcomes in patients with chronic heart
failure (CHF). METHODS: National retrospective cohort of Veterans Affairs (VA) 
patients, with at least one outpatient claim of CHF between October 1, 1996 and
September 30, 2001 (end of FY01), was identiﬁ ed. Exposure and outcomes were 
assessed in FY 2001 and FY 2002, respectively. ACEI/BB therapy was deﬁ ned as 
patients taking ACEI/BB with MPR (Medication Possession Ratio) 0.8 in exposure 
period. Outcomes were hospitalizations (all cause and heart failure) and total 
costs (inpatient, outpatient and pharmacy costs). Multivariate regression analysis 
was employed to determine outcome estimates; adjusted for socio-demographics, 
30 co-morbidities, co-medications and disease severity as measured by years with
heart failure. RESULTS: Total cohort comprised of 230,406 patients with mean 
age 69.96 o 10.39 years, 98% were men and 48% were whites. Of the total
cohort 89,757 (38.96%) were on ACEI therapy and 67,348 (29.23%) on BB therapy. 
Hypertension was the most prevalent comorbidity (78.76%). For all cause hospitaliza-
tion, BB was associated with 3.1% reduced risk (Adjusted OR: 0.969, 95% CI: 
0.944–0.994), whereas ACEI did not show any signiﬁ cant change (Adjusted OR: 1.0, 
95% CI: 0.98–1.029). For HF hospitalizations, BB reduced risk by 14.3% (Adjusted 
OR: 0.857, 95% CI: 0.812–0.904), whereas ACEI showed increased risk (Adjusted 
OR: 1.082, 95% CI: 1.029–1.137). Both therapies were associated with signiﬁ cant 
increase in costs compared to patients not receiving these medications (ACEI 5.3%, 
p  0.0001; BB 7%, p  0.0001). CONCLUSIONS: BB was associated with signiﬁ -
cantly reduced risk of all cause and HF hospitalizations, while ACEI did not show 
signiﬁ cant protective effect. Both therapies were found to increase total costs, suggest-
ing the need for more studies to examine cost-effective therapies for patients in routine 
clinical settings.
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OBJECTIVES: Statin medications are recommended for patients who have not 
achieved LDL-C goals through lifestyle modiﬁ cations. Little information exists regard-
ing the use of statins and LDL-C goal attainment among employed populations. This 
retrospective, observational study examined the statin medication usage pattern and 
the relationship between statin usage and LDL-C goal levels (according to ATP III 
guidelines) among a cohort of employees of a major ﬁ nancial services corporation.
METHODS: From 1995 to 2004, a total of 1,607 executives (average age 49.1, s.d. 
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7.6; 37% female, 63% male) participated in a health examination which included a 
lipid proﬁ le. An index date was assigned for each study participant using the date of 
their exam and statin medication usage was determined through the pharmacy claims 
database for 365 days before the index date. Patients were identiﬁ ed as adherent to 
statins if their medication possession ratio (MPR) was at least 80%. RESULTS: Statin
use increased over the study period with 150 (9.3%) executives ﬁ lling at least one 
statin prescription in the 365 days prior to their exam. A total of 102 statin users
(68%) were adherent to statin medication. Among all patients who received statin 
treatment, 70% (OR  2.33, 95% CI  1.54, 3.51) achieved near optimal ( 130 mg/
dL) and 30% (OR  1.78, 95% CI  1.15, 2.76) achieved optimal ( 100 mg/dL)
LDL-C goals which are signiﬁ cantly higher than the rates among statin non-users 
(55% and 21%). Both adherent statin users and nonadherent statin users were more 
likely to achieve recommended near optimal LDL-C goals compared to executives who
were not taking statins (overall p  0.002; adherent: OR  2.75, 95%CI 1.662, 4.550; 
nonadherent: OR  1.70, 95% CI 0.884, 3.268.) CONCLUSIONS: Among executives
who participated in a periodic health examination, statin usage appears to be associ-
ated with improvements in LDL-C goal attainment. Appropriate medication usage and 
adherence to medication should be encouraged in working populations.
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OBJECTIVES: To determine the effect of ACE Inhibitors/ARBs and statins on the
incidence of dementia, in patients with Chronic Heart Failure (CHF). METHODS:
A national retrospective cohort of Veterans Affairs (VA) patients, with at least 
one outpatient claim of CHF from October 1, 1996 to September 30, 2000,
was identiﬁ ed. Drug exposure was analyzed from October 1, 1998 to September
30, 2000 and outcome of dementia (yes/no) was identiﬁ ed, based on ICD-9-CM
codes, from October 1, 2000 to September 1, 2002. Patients with non-utilization of 
VA services for two years and prevalent cases of dementia were excluded. A Cox
proportional hazards model of time to dementia diagnosis was constructed to test the
association of drug use with dementia, adjusted for socio-demographics, co-morbidi-
ties and co-medications. RESULTS: Out of 242,734 patients, 2.77% developed 
dementia during follow-up. About 75% were elderly and 79% had hypertension. 
Females, African-Americans had signiﬁ cantly higher risk of dementia than males, 
whites, respectively. Risk of dementia increased progressively with age. In adjusted 
analyses, hypertension (HR: 1.157, 95% CI: 1.078–1.240), diabetes (HR: 1.105, 95% 
CI: 1.051–1.161), and cerebrovascular disease (HR: 1.577, 95% CI: 1.489–1.671) 
signiﬁ cantly increased risk of dementia. Adjusted analyses of one-year (HR: 0.988, 
95% CI: 0.911–1.071) or two-year (HR: 0.991, 95% CI: 0.930–1.057) exposure 
to ACE Inhibitors did not signiﬁ cantly affect dementia. Adjusted analyses of one-
year exposure to ARBs (HR: 0.784, 95% CI: 0.634–0.969), statins (HR: 0.906, 
95% CI: 0.839–0.979) and two-year exposure to ARBs (HR: 0.711, 95% CI: 
0.594–0.852), statins (HR: 0.884, 95% CI: 0.829–0.943) had protective effect on
incidence of dementia. Two-year drug exposure had increased protective effect, com-
pared to one-year exposure. CONCLUSIONS: Study suggests potential beneﬁ cial 
effects, to delay onset of dementia, associated with use of ARBs and statins. Thus, 
prescribing of such agents in pharmacotherapeutic regimens of CHF patients should 
be encouraged.
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ESTIMATE THE 10-YEAR CARDIOVASCULAR RISK IN THE GENERAL
PUBLIC OF HONG KONG
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OBJECTIVES: Coronary heart disease (CHD) is a major health issue in Hong Kong
and has become the second leading cause of death since the 1960s. Figures from the 
Hong Kong Department of Health Statistics have shown that in the year 2005, 
approximately 11 persons died from CHD each day. The prevalence of CHD and its
mortality in Hong Kong are approaching a level that requires focused attention.
Unfortunately, CHD could be a silent disease until the manifestations occur. Therefore, 
early detection and control of cardiovascular risk factors including cholesterol and
blood pressure is vital. In view of this point, the current project aimed to investigate 
the 10-year cardiovascular risk in the general public of Hong Kong. METHODS: A
12-month prospective public screening of lipid panels and blood pressure for the esti-
mation of 10-year cardiovascular risk was conducted in the general public of Hong 
Kong between April 2007 and April 2008. RESULTS: During this period, a total of 
2,607 patients were recruited with the mean age of 46.4/11.1 years old (51.3%
male) and 8.1% of subjects were active smokers. Among all of the subjects, the mean
total cholesterol was 5.42/1.28 mmol/L and the mean high density cholesterol was
1.59/0.75 mmol/L. The mean systolic blood pressure was 121.7/19.5 mmHg. The
assessment of the 10-year cardiovascular risk showed that 13.8% of the subjects were
moderately high to high risk patients. CONCLUSIONS: The project demonstrated
that the general public in Hong Kong had relatively high total cholesterol and normal-
high systolic blood pressure. There were almost 2 in every 10 Hong Kong citizens may
have a 10–20% or more than 20% risk to develop CHD in the next 10 years. As a 
result, good lifestyle modiﬁ cation and regular health screening are essential and 
urgently required to lower the cardiovascular risk in the general public of Hong 
Kong.
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OBJECTIVES: National estimates of cardiovascular risk factor prevalence, awareness, 
treatment, and control among adults without health insurance are lacking. This study 
contributes to our knowledge by examining current national estimates for hyperten-
sion, dyslipidemia, and diabetes among uninsured, non-Medicaid insured, and 
Medicaid-insured adults aged 18 through 64 years. METHODS: Cross-sectional
observational study design. Analysis of adults 18 through 64 years of age surveyed in 
the National Health and Nutrition Examination Survey (NHANES) 2003–2006 (N 
8,500). RESULTS: Of an estimated 178.6 million working-age adults, 21.8% (95%
conﬁ dence interval [CI]  19.6%– 24.1%) lack health insurance. Hypertension preva-
lence is signiﬁ cantly lower in the uninsured compared with the non-Medicaid insured 
(18.9% and 21.8%, age and gender adjusted) as are rates of awareness (62.8% vs 
77.0%) and treatment (43.9% vs 65.5%). Medicaid-insured adults have a signiﬁ cantly 
higher prevalence of hypertension (29.1%) than the non-Medicaid insured. There is
no signiﬁ cant difference between the uninsured and non-Medicaid insured with respect
to adjusted prevalence of dyslipidemia (27.4% and 25.3%) or type-2 diabetes (6.4%
and 6.0%). Awareness and treatment rates for dyslipidemia are signiﬁ cantly lower in
the uninsured compared with the non-Medicaid insured (38.8% vs 64.7% for aware-
ness; 18.0% vs 41.4% for treatment). Treatment rates for diabetes are also signiﬁ -
cantly lower for the uninsured (39.9% vs 62.5%). Multivariable logistic regression
controlling for age, gender, race, education, access to care, and marital status indicate
that the uninsured are signiﬁ cantly less likely than the non-Medicaid insured to be 
aware of and treated for their dyslipidemia and less likely to be treated for their dia-
betes. CONCLUSIONS: Dyslipidemia and diabetes are less likely to be detected or 
treated among the uninsured compared with the non-Medicaid insured, calling for 
effective approaches to reduce these disparities.
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OBJECTIVES: The purpose of this study was to examine whether there is a difference 
in the seasonal, weekly and daily variation of acute myocardial infarction in patients
who were diabetic and who were not, and to get information about the mechanism 
of the background of the rhythm variation and about the triggering effects. METHODS:
Retrospective analysis was made with acute myocardial infarction patients received in
almost all hospitals in Hungary between 2005 and 2007 (n  41.510, 23.993 male, 
17.517 female). Data were collected from the database of the National Health Insur-
ance Fund Administration based on ICD codes: I21, I22, E1000–1490. RESULTS:
With regard to seasonal variation, the peek period of acute myocardial infarction was
found during the months of spring, the lowest number of events is during the summer.
There was a signiﬁ cant difference between the number of events for each season (p 
0.003). The weekly peek period of acute myocardial infarction was found on the ﬁ rst
day of the week, on Monday, with a gradually decreasing tendency towards the end 
of the week, until Sunday. The decrease is much higher in the weekend. Regarding the 
daily rhythm, the results were signiﬁ cant. The peek period was found in the morning
hours of the day, and the lowest number of acute myocardial infarction was in the 
evening hours (p  0,001). In case of patients with diabetes (5.739 male, 5.376 female) 
the results were similar, the seasonal variation in the occurrence of acute myocardial 
infarction is also signiﬁ cant, such as the results of the weekly and daily rhythm (p 
0.025, p  0.000). CONCLUSIONS: In summary, it can be said that the results of our 
study show that the incidence of an acute myocardial infarction shows characteristic 
variation with regard to seasons and the days of the week, but there are no differences 
between diabetic and non-diabetic patients.
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OBJECTIVES: The purpose of our study was to observe whether a seasonal change
or weekly variation can be shown in the incidence of an acute myocardial infarction 
(AMI) and a transient ischemic attack (TIA) during a three-year study period in 
Hungary. We also examined whether the occurrence of an AMI or a TIA is inﬂ uenced
by age and sex. METHODS: We have analyzed AMI (N  51,802) and TIA (N 
12,592) patients received at clinics and hospitals in Hungary between 2005 and 2007.
Data were collected from the database of the National Social Security Fund (OEP) 
based on the International Classiﬁ cation of Diseases (ICD codes). RESULTS: Based 
on our results, a weekly and a seasonal variation can be seen in the onset of a transient 
ischemic attack and an acute myocardial infarction. With regard to seasonal variation, 
there was a signiﬁ cant difference between the number of events for each season (p 
0.01), and the peek period of AMI and TIA was found during the months of spring, 
the lowest number of events of AMI is during the summer and in the case of TIA is 
in autumn. In case of sexes, difference was only found in the seasonal variation of 
number of events of AMI (p  0.01). The weekly peek period of infarction and cerebral 
